Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shire
Biotech
Ex-Shire drug improves outcomes in phase 2 autoimmune trial
Nine years after Shire paid $75 million for FT011, Certa linked the candidate to improvements in the symptoms of a rare autoimmune disease in phase 2.
Nick Paul Taylor
Feb 6, 2023 6:15am
FDA shores up executive team with 2 hires—Chutes & Ladders
Jul 1, 2022 9:30am
Takeda scraps dream of getting rare disease drug to market
May 11, 2022 8:30am
Biogen CEO steps down after Aduhelm blunder—Chutes & Ladders
May 6, 2022 9:30am
Takeda shunts jewel of Shire takeover to new spinoff Oak Hill
Feb 1, 2022 8:30am
Sage's COO and bluebird's CMO to hit the exit—Chutes & Ladders
Mar 19, 2021 9:30am